---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-009775"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:42:18.300831+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma appoints Keith Murphy and Edward Neugeboren to board; two directors resign

## Summary
- Natasha Giordano and Matthew Wikler resigned from the Board effective Feb 11, 2025, not due to any disagreement.
- Keith Murphy (Organovo Executive Chairman) appointed director, Chair of Governance Committee, Compensation Committee member.
- Edward Neugeboren (Cronus Pharma Chief Strategy Officer) appointed director, Chair of Compensation, Audit Committee member.
- Neugeboren qualifies as audit committee financial expert; both are independent under NYSE and SEC rules.
- New directors bring significant healthcare, biotech, and capital markets experience; effective March 11, 2025.

## SEC filing metadata
- accession: 0001493152-25-009775
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315225009775/0001493152-25-009775-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315225009775/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-009775
- JSON: https://secwatch.observer/filing/0001493152-25-009775.json
- Plain text: https://secwatch.observer/filing/0001493152-25-009775.txt

## Key facts
- Executive change
  Edward Neugeboren was appointed as Director at Matinas BioPharma Holdings, Inc..
  - Action: appointed
  - Role: Director
  source text: The Board appointed Mr. Neugeboren to serve as a member of the Audit Committee and as Chair of the Compensation Committee.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315225009775/0001493152-25-009775-index.htm
- Executive change
  Natasha Giordano resigned as Director at Matinas BioPharma Holdings, Inc..
  - Action: resigned
  - Role: Director
  source text: On February 10, 2025, Natasha Giordano informed the Board of Directors (the “ Board ”) of Matinas BioPharma Holdings, Inc. (the “ Company ”) that she was resigning from the Board effective February 11, 2025, due to her other professional obligations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315225009775/0001493152-25-009775-index.htm
- Executive change
  Matthew Wikler resigned as Director at Matinas BioPharma Holdings, Inc..
  - Action: resigned
  - Role: Director
  source text: On February 10, 2025, Matthew Wikler informed the Board that he was resigning from the Board effective February 11, 2025, due to his other professional obligations.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315225009775/0001493152-25-009775-index.htm
- Executive change
  Keith Murphy was appointed as Director at Matinas BioPharma Holdings, Inc..
  - Action: appointed
  - Role: Director
  source text: Effective as of March 11, 2025, the Board, on the recommendation of the Governance Committee, appointed Keith Murphy and Edward Neugeboren directors of the Company to replace Ms. Giordano and Mr. Wikler, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1582554/000149315225009775/0001493152-25-009775-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.